{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:15:07Z","timestamp":1760220907212,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002649","name":"Yeungnam University","doi-asserted-by":"publisher","award":["2016A380227"],"award-info":[{"award-number":["2016A380227"]}],"id":[{"id":"10.13039\/501100002649","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hfc.2025.06.004","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:00:04Z","timestamp":1753156804000},"page":"533-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evolving Landscape of Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"21","author":[{"given":"Jang-Won","family":"Son","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Ho","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-Un","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geu-Ru","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9862","key":"10.1016\/j.hfc.2025.06.004_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"issue":"39","key":"10.1016\/j.hfc.2025.06.004_bib2","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"issue":"37","key":"10.1016\/j.hfc.2025.06.004_bib3","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"12 Suppl 3","key":"10.1016\/j.hfc.2025.06.004_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: an update on diagnosis and treatment","volume":"84","author":"Hanna","year":"2017","journal-title":"Cleve Clin J Med"},{"issue":"16","key":"10.1016\/j.hfc.2025.06.004_bib5","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.hfc.2025.06.004_bib6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American college of cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.hfc.2025.06.004_bib7","first-page":"3384","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"110","author":"Dispenzieri","year":"2004","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.hfc.2025.06.004_bib8","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.hfc.2025.06.004_bib9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jcmg.2018.06.016","article-title":"Relative apical sparing of myocardial longitudinal strain is explained by regional differences in total amyloid mass rather than the proportion of amyloid deposits","volume":"12","author":"Bravo","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"30","key":"10.1016\/j.hfc.2025.06.004_bib10","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.hfc.2025.06.004_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41569-020-0334-7","article-title":"Diagnostic imaging of cardiac amyloidosis","volume":"17","author":"Martinez-Naharro","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"24","key":"10.1016\/j.hfc.2025.06.004_bib12","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"28","key":"10.1016\/j.hfc.2025.06.004_bib13","first-page":"1839","article-title":"Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study","volume":"36","author":"Kandolin","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hfc.2025.06.004_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.113.000867","article-title":"Evaluation of known or suspected cardiac sarcoidosis","volume":"9","author":"Blankstein","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.hfc.2025.06.004_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jacc.2016.03.605","article-title":"Cardiac sarcoidosis","volume":"68","author":"Birnie","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2025.06.004_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2967\/jnumed.111.090662","article-title":"The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and meta-analysis including the Ontario experience","volume":"53","author":"Youssef","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.hfc.2025.06.004_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.hfc.2025.06.004_bib18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/jhg.2016.52","article-title":"Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis","volume":"61","author":"Seo","year":"2016","journal-title":"J Hum Genet"},{"issue":"3","key":"10.1016\/j.hfc.2025.06.004_bib19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/10976640600605002","article-title":"The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease","volume":"8","author":"Moon","year":"2006","journal-title":"J Cardiovasc Magn Reson"},{"issue":"23","key":"10.1016\/j.hfc.2025.06.004_bib20","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: evidence for a disease-specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.hfc.2025.06.004_bib21","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","article-title":"Proposed stages of myocardial phenotype development in Fabry disease","volume":"12","author":"Nordin","year":"2019","journal-title":"J Am Coll Cardiol Img"},{"issue":"4","key":"10.1016\/j.hfc.2025.06.004_bib22","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hfc.2025.06.004_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hfc.2025.06.004_bib24","first-page":"261","article-title":"Pompe\u2019s disease","volume":"31","author":"van der Ploeg","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"17","key":"10.1016\/j.hfc.2025.06.004_bib25","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.3390\/jcm12175710","article-title":"Revisiting diagnosis and treatment of hypertrophic cardiomyopathy: current practice and novel perspectives","volume":"12","author":"Pelliccia","year":"2023","journal-title":"J Clin Med"},{"issue":"6798","key":"10.1016\/j.hfc.2025.06.004_bib26","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/35022604","article-title":"Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)","volume":"406","author":"Nishino","year":"2000","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.hfc.2025.06.004_bib27","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMoa2412392","article-title":"Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease","volume":"392","author":"Sabatine","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2025.06.004_bib28","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.CIR.91.4.955","article-title":"Cardiac involvement in mitochondrial diseases: a study on 17 patients with documented mitochondrial DNA defects","volume":"91","author":"Anan","year":"1995","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.hfc.2025.06.004_bib29","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2022.08.719","article-title":"Cardiac disease in patients with mitochondrial defects: 2 steps forward and 1 step back","volume":"80","author":"Ware","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"6302","key":"10.1016\/j.hfc.2025.06.004_bib30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/348651a0","article-title":"A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies","volume":"348","author":"Goto","year":"1990","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.hfc.2025.06.004_bib31","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0735-1097(02)02270-2","article-title":"Physiologic limits of left ventricular hypertrophy in elite junior athletes: relevance to differential diagnosis of athlete\u2019s heart and hypertrophic cardiomyopathy","volume":"40","author":"Pelliccia","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.hfc.2025.06.004_bib32","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.jacc.2007.12.061","article-title":"Ethnic differences in left ventricular remodeling in highly-trained athletes: relevance to differentiating physiologic left ventricular hypertrophy from hypertrophic cardiomyopathy","volume":"51","author":"Basavarajaiah","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2025.06.004_bib33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199101313240504","article-title":"The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes","volume":"324","author":"Maron","year":"1991","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hfc.2025.06.004_bib34","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.3390\/jcm12103481","article-title":"Cardiac magnetic resonance in HCM phenocopies: from diagnosis to risk stratification and therapeutic management","volume":"12","author":"Niccoli-Asabella","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.hfc.2025.06.004_bib35","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s10741-020-09943-x","article-title":"Comprehensive assessment of hypertensive heart disease: cardiac magnetic resonance in focus","volume":"26","author":"Tadic","year":"2021","journal-title":"Heart Fail Rev"},{"issue":"6","key":"10.1016\/j.hfc.2025.06.004_bib36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jacc.2021.05.047","article-title":"Markers of myocardial damage predict mortality in patients with aortic stenosis","volume":"78","author":"Kwak","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2025.06.004_bib37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.hfc.2025.06.004_bib38","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American heart association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hfc.2025.06.004_bib39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13244-018-0655-9","article-title":"Differential diagnosis of thickened myocardium: an illustrative MRI review","volume":"9","author":"M\u00e9ndez","year":"2018","journal-title":"Insights Imaging"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713625000534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713625000534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:39:23Z","timestamp":1760218763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713625000534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1551713625000534"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2025.06.004","relation":{},"ISSN":["1551-7136"],"issn-type":[{"type":"print","value":"1551-7136"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Landscape of Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2025.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}